GlassScriptPhysician profile
David G Patterson
NPI 1881682821
$15,147.25
in general payments reported to CMS, 2019-2025
61 companies · $2,895 in 2025
The $2,895 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,217 · 2020: $1,256 · 2021: $2,453 · 2022: $2,427 · 2023: $2,090 · 2024: $2,809 · 2025: $2,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,694 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,693.93 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,588.54 | 2020-2025 | |
| Lilly USA, LLC | $1,157.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,060.32 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $1,022.08 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $897.59 | 2019-2025 | |
| Glaxosmithkline, LLC. | $816.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $710.81 | 2019-2023 | Livalo, Seglentis |
| Amgen INC. | $700.51 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $612.47 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $449.83 | 2019-2025 | Farxiga, Airsupra, Flumist Quadrivalent |
| Otsuka America Pharmaceutical, INC. | $449.77 | 2021-2025 | Rexulti |
| Ardelyx, INC. | $428.64 | 2024-2025 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $372.28 | 2022-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $367.46 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Exact Sciences Corporation | $333.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.